Pulse Biosciences (PLSE) Shoots Up 16%

The significant rise in stock price follows a rights offering that was announced a week ago. Pulse announced its intention to issue”non-transferable subscription rights to its stockholders of record as of the Record Date to purchase up to $15,000,000 of units (the “Units,” and each, a “Unit”) at a subscription price per Unit equal to the lesser of (i) $3.72 per share, the closing price of the Common Stock on April 13, 2022 (the “Initial Price”) and (ii) the volume weighted average price of the Common Stock for the five-trading day period through and including the subscription expiration date (the “Alternate Price”)”

Despite the positive day for PLSE, the stock is still vastly far away from its 52-week high of $29.16.

Pulse Biosciences is housed in the PRISM Medical Devices Index, which, despite PLSE’s surge, has fallen 2.3% for the day.

About Pulse Biosciences®
Pulse Biosciences is a novel bioelectric medicine company committed to health innovation that has the potential to improve the quality of life for patients. The Company’s proprietary Nano-Pulse Stimulation technology delivers nano-second pulses of electrical energy to non-thermally clear cells while sparing adjacent non-cellular tissue. The CellFX® System is the first commercial product to harness the distinctive advantages of NPS technology to treat a variety of applications for which an optimal solution remains unfulfilled. The initial commercial use of the CellFX System is to address a range of dermatologic conditions that share high demand among patients and practitioners for improved dermatologic outcomes. Designed as a multi-application platform, the CellFX System offers customer value with a utilization-based revenue model. Visit pulsebiosciences.com to learn more.

Share This Article

 

About the Author

Pulse Biosciences (PLSE) Shoots Up 16%

Editor Prism MarketView